|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current status and recent advances of liver transplantation from donation after cardiac death显示文摘The last decade saw increased organ donation activity from donors after cardiac death (DCD). This contributed to a signif icant proportion of transplant activity. Despite certain drawbacks, liver transplantation from DCD donors continues to supplement the donor pool on the backdrop of a severe organ shortage. Understanding the pathophysiology has provided the basis for modulation of DCD organs that has been proven to be effective outside liver transplantation but remains experimental in liver transplantation models. Research continues on how best to further increase the utility of DCD grafts. Most of the work has been carried out exploring the use of organ preservation using machine assisted perfusion. Both ex-situ and in-situ organ perfusion systems are tested in the liver transplantation setting with promising results. Additional techniques involved pharmacological manipulation of the donor, graft and the recipient. Ethical barriers and end-of-life care pathways are obstacles to widespread clinical application of some of the recent advances to practice. It is likely that some of the DCD offers are in fact probably 'prematurely' of-fered without ideal donor management or even prior to brain death being established. The absolute benef its of DCD exist only if this form of donation supplements the existing deceased donor pool; hence, it is worthwhile revisiting organ donation process enabling us to identify counter remedial measures. | M Thamara PR Perera Simon R Bramhall | 2011 | World Journal of Gastrointestinal Surgery2011，3，11： | 16 |
| 2 | Aetiology and risk factors of ischaemic cholangiopathy after liver transplantation显示文摘Liver transplantation(LT)is the best treatment for endstage hepatic failure,with an excellent survival rates over the last decade.Biliary complications after LT pose a major challenge especially with the increasing number of procured organs after circulatory death.Ischaemic cholangiopathy(IC)is a set of disorders characterized by multiple diffuse strictures affecting the graft biliary system in the absence of hepatic artery thrombosis or stenosis.It commonly presents with cholestasis and cholangitis resulting in higher readmission rates,longer length of stay,repeated therapeutic interventions,and eventually re-transplantation with consequent effects on the patient’s quality of life and increased health care costs.The pathogenesis of IC is unclear and exhibits a higher prevalence with prolonged ischaemia time,donation after circulatory death(DCD),rejection,and cytomegalovirus infection.The majority of IC occurs within 12 mo after LT.Prolonged warm ischaemic times predispose to a profound injury with a subsequently higher prevalence of IC.Biliary complications and IC rates are between 16%and 29%in DCD grafts com-pared to between 3%and 17%in donation after brain death(DBD)grafts.The majority of ischaemic biliary lesions occur within 30 d in DCD compared to 90 d in DBD grafts following transplantation.However,there are many other risk factors for IC that should be considered.The benefits of DCD in expanding the donor pool are hindered by the higher incidence of IC with increased rates of re-transplantation.Careful donor selection and procurement might help to optimize the utilization of DCD grafts. | Moustafa Mabrouk Mourad Abdullah Algarni Christos Liossis Simon R Bramhall | 2014 | World Journal of Gastroenterology2014，20，20： | 16 |
| 3 | Pancreatitis: Preventing catastrophic haemorrhage显示文摘Pancreatitis represents nearly 3% of acute admissions to general surgery in United Kingdom hospitals and has a mortality of around 1%-7% which increases to around 10%-18% in patients with severe pancreatitis. Patients at greatest risk were those identified to have infected pancreatic necrosis and/or organ failure. This review seeks to highlight the potential vascular complications associated with pancreatitis that despite being relatively uncommon are associated with mortality in the region of 34%-52%. We examine the current evidence base to determine the most appropriate method by which to image and treat pseudo-aneurysms that arise as the result of acute and chronic inflammation of pancreas. We identify how early recognition of the presence of a pseudo-aneurysm can facilitate expedited care in an expert centre of a complex pathology that may require angiographic, percutaneous, endoscopic or surgical intervention to prevent catastrophic haemorrhage. | Richard PT Evans Moustafa Mabrouk Mourad Gunraj Pall Simon G Fisher Simon R Bramhall | 2017 | World Journal of Gastroenterology2017，23，30： | 6 |
| 4 | Anticoagulation and antiplatelets as prophylaxis for hepatic artery thrombosis after liver transplantation显示文摘Hepatic artery thrombosis(HAT) is the most serious vascular complication after liver transplantation. Multiple risk factors have been identified to impact its development. Changes in haemostasis associated with end stage liver disease and the disturbance of the coagulation and anticoagulation cascades play an important role in development of this lethal complication. Early recognition and therapeutic intervention is mandatory to avoid its consequences. Pharmacological prophylaxis, by the use of antiplatelet or anticoagulant agents, is an important tool to reduce its incidence and prevent graft loss. Only a few studies have shown a clear benefit of antiplatelet agents in reducing HAT occurrence, however, these studies are limited by being retrospective and by inhomogeneous populations. The use of anticoagulants such as heparin is associated with an improvement in the outcomes mainly when used for a high-risk patients like living related liver recipients. The major concern when using these agents is the tendency to increase bleeding complications in a setting of already unstable haemostasis. Hence, monitoring of their administration and careful selection of patients to be treated are of great importance. Well-designed clinical studies are still needed to further explore their effects and to formulate proper protocols that can be implemented safely. | Abdullah A Algarni Moustafa M Mourad Simon R Bramhall | 2015 | World Journal of Hepatology2015，7，9： | 2 |
| 5 | 分子技术在胰腺癌治疗中的应用显示文摘 | Zahir Soonawalla Simon Bramhall 黄昕 | 2003 | 中国实用外科杂志2003，23，10： | 2 |
| 6 | Low mortality following resection for pancreatic and periampullary tumours in 1026 patients:UK survey of specialist pancreatic units显示文摘 | Neoptolemos JP Russel RC Bramhall S | 1997 | Br J Surg1997，84，： | 2 |
| 7 | Marimastat as maintenance therapy for patients with advanced gastric cancer:a randomised trial显示文摘 | Bramhall SR Hallissey MT Whiting J | 2002 | Br J Cancer2002，86，12： | 1 |
| 8 | Low mortality following resection for pancreatic and periampuUary turnouts in 1026 patients: UK survey of pancreatic specialist units显示文摘 | Neoptolemos JP Russell RCG Bramhall S | 1997 | Br J Surg1997，84，： | 1 |
| 9 | Repeat liver resection for recurrent colorectal metastases: a single‐centre, 13‐year experience显示文摘 | Narendra Battula Dimitrios Tsapralis David Mayer John Isaac Paolo Muiesan Robert P. Sutcliffe Simon Bramhall Darius Mirza Ravi Marudanayagam | 2014 | HPB2014，，2： | 1 |
| 10 | Enhanced expression of matrix metalloproteinases is often unopposed by their inhibitors (tissue inibitors of metalloproteinases) in pancreatic cancer 显示文摘 | Bramhall SR L emoine NR Stamp GWH | 1997 | Br J Surg1997，84，1： | 1 |
| 11 | A study of the metabolites of ischemia -reperfusion injury and selected amino acids in the liver using microdialysis during transplantation显示文摘 | Silva M A Richards D A Bramhall S R | 2005 | Transplantation2005，79，7： | 1 |
| 12 | Traumatic focal pancreatitis with ret?ro-duodenal hematoma: a rare cause of combined biliary and gastric outlet obstruction显示文摘 | Scalera I Kumar S Bramhall S | 2012 | JOP2012，13，6： | 1 |
| 13 | A Study of the metabolites of ischemia-reperfusion injury and selected amino acids in the Liver using microdialysis during transplantation 显示文摘 | Silva MA Richards DA Bramhall SR | 2005 | Transplantation2005，79，7： | 1 |
| 14 | Lgr5-positive supporting cells generate new hair cells in the postnatal cochlea显示文摘 | Bramhall NF Shi F Arnold K | 2014 | Stem Cell Reports2014，2，3： | 1 |
| 15 | Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial显示文摘 | Bramhall SR Hallissey MT Whiting J | 2002 | Br J Cancer2002，86，12： | 1 |
| 16 | Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma 显示文摘 | Bramhall SR Neoptolemos JP Stamp GW | 1997 | J Pathol1997，182，3： | 1 |
| 17 | A double-blind placebo-controlled,randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer 显示文摘 | Schulz J Nemunaitis J | 2002 | Br J Cancer2002，，： | 1 |
| 18 | Marimastat as maintenance therapy for patients with advanced gastric cancer:a randomised trial显示文摘 | Bramhall SR Hallissey MT Whiting J | 2002 | Br J Cancer2002，86，12： | 1 |
| 19 | Outcomes comparing a pancreaticogastrostomy (PG) and a pancreaticojejunostomy (PJ) after a pancreaticoduodenectomy (PD) 显示文摘 | Aroori S Puneet P Bramhall SR | 2011 | HPB (Oxford)2011，13，10： | 1 |
| 20 | Marimastat as a firstline therapy for patients with unresectable pancreatic cancer : a randomized trial显示文摘 | Bramhall SR Rosemurgy A Brown PD | 2001 | J Clin Oncol2001，19，15： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员